Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Product | Size | Amount |
ActiveMax® Human CD7 μBeads, premium grade (for cells) | 2.5 mg | 2.5 × 10⁷ beads |
ActiveMax® Human CD7 μBeads, premium grade (for cells) | 10 mg (2.5 mg × 4) | 1.0 × 10⁸ beads |
See Certificate of Analysis (CoA) for detailed instruction.
Please contact us for detailed information.
Contact us for customized product form or formulation.
Assay of human CD7 protein on the μBeads surface by Flow cytomtry.ActiveMax® Human CD7 μBeads, premium grade (for cells) (Cat. No. MBS-C005) were stained with anti-human CD7 antibody, and then followed by FITC anti-human IgG Fc antibody and analyzed by flow cytometry.
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy | GC-197 | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
BEAM-201 | BEAM-201 | Phase 2 Clinical | Beam Therapeutics Inc | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, T-Cell | Details |
Autologous and Donor-derived CD7 CAR-T Therapy(Beijing GoBroad Hospital) | Phase 2 Clinical | Beijing GoBroad Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD7-CAR-T Cells Therapy | CD7-CART01 | Phase 2 Clinical | Bambino Gesu Hospital And Research Institute | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
Humanized CD7 CAR-T cells | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University | Lymphoma, T-Cell | Details | |
WU-CART-007 | WU-CART-007 | Phase 2 Clinical | Wugen Inc | Lymphoma, T-Cell, Peripheral; Enteropathy-Associated T-Cell Lymphoma; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, Extranodal NK-T-Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sezary Syndrome; Lymphoma, Large-Cell, Anaplastic; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Leukemia, Prolymphocytic, T-Cell; Mycosis Fungoides | Details |
Anti-CD7 CAR T-cell therapy (Yake Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Leukemia; Still's Disease, Adult-Onset; Hematologic Diseases; Dermatomyositis; Neoplasms; Autoimmune Diseases; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Colitis, Ulcerative; Lymphoma; Lymphoma, T-Cell; Crohn Disease; Leukemia, T-Cell | Details | |
CD7-CAR-T cell therapy (PersonGen Biomedicine) | Phase 2 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd, The First Affiliated Hospital Of Zhengzhou University | Leukemia; Enteropathy-Associated T-Cell Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large-Cell, Anaplastic; Leukemia, Myeloid, Acute; Lymphoma, T-Cell | Details | |
GC-027 | GC-027 | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
MB-107(March Biosciences) | MB-107(March Biosciences) | Phase 1 Clinical | March Biosciences Inc | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell | Details |
Universal 4SCAR7U T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR7U T cells | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lymphoma | Details |
RD13-02 | RD13-02 | Phase 1 Clinical | Nanjing Bioheng Biotech Co Ltd, Zhejiang University | Hematologic Neoplasms; Hematologic Diseases; Neoplasms | Details |
Anti-CD7 Chimeric Antigen Receptor T-Cell therapy(Bioceltech Therapeutics) | BT-007 | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd, Bioceltech Therapeutics Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |
BE CAR-7 | BE-CAR-7 | Phase 1 Clinical | Great Ormond Street Hospital For Children Nhs Foundation Trust | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Prolymphocytic, T-Cell | Details |
Anti-CD7 CAR-T cell Therapy (Shanghai General Hospital) | Phase 1 Clinical | Shanghai General Hospital | Lymphoma, T-Cell, Peripheral; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Large-Cell, Anaplastic; Leukemia, T-Cell | Details | |
This CAR-T-7 cells therapy | This CAR-T-7 cells | Phase 1 Clinical | Fundamenta Therapeutics Ltd | Leukemia, Lymphoid; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell | Details |
GC-502 | GC-502 | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD7 CARvac T cell therapy | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Hematologic Neoplasms; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma | Details | |
SenL-T7 CAR T Cells (Hebei Senlang Biological) | Senl-T7; Senl-T-7; SENL-101 | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell; Leukemia, T-Cell | Details |
PA3-17 | PA3-17; PA-3-17; PA3-17 (autologous) | Phase 1 Clinical | Persongen Anke Cell Technology Co Ltd, Persongen Biotherapeutics (Suzhou) Co Ltd | Hematologic Neoplasms; Lymphoma | Details |
CAR7-T Cell Therapy (Beijing Gaobo Biotechnology Co Ltd) | Phase 1 Clinical | Wuhan Union Hospital | Lymphoma, T-Cell; Leukemia, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD7 targeted CAR-γδ T cells therapy(Persongen Bio) | Phase 1 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Neoplasms; Leukemia, B-Cell | Details | |
CD7 CAR-T cell therapy (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
RD13-01 | RD13-01; CTD-401 | Clinical | Zhejiang University, Nanjing Bioheng Biotech Co Ltd | Hematologic Neoplasms | Details |
Anti-CD7 CAR-T Cell Therapy (iCell Gene Therapeutics) | iCell Gene Therapeutics LLC | Details |
This web search service is supported by Google Inc.